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AbstrAct
The prognosis of non-small cell lung cancer (NSCLC) remains poor and 
heterogeneous and new biomarkers are needed. As the immune system plays a 
pivotal role in cancer, the study of immune-related markers may provide valuable 
prognostic information of NSCLC. In 122 formalin-fixed, paraffin-embedded tumor 
tissue samples from early-stage NSCLC, tumor and tumor-near stromal areas were 
microdissected and gene expression levels of conventional and regulatory T cell 
markers were assessed by quantitative polymerase chain reaction. Also, the presence 
of infiltrating CD4+, CD8+, and FOXP3+ cells in tumor samples was assessed by 
immunohistochemistry. The relative proportion of conventional and regulatory T cells 
present in the tumor environment was assessed and found to be key to understand the 
importance that the immune system analysis has in the prognostics of NSCLC patients. 
The presence of CD8+ cells in the tumor compartment was associated with better 
outcome, whereas the presence of FOXP3+ cells was associated with worse overall 
survival. The negative prognostic value of combined biomarkers, indicating high levels 
of FOXP3 in the stroma and low levels of CD4 or CD8 in tumors, was observed at mRNA 
level and was validated by immunohistochemistry.In conclusion, the proportion of 
T helper and cytotoxic cells vs. regulatory T cells in different locations of the tumor 
microenvironment have opposite prognostic impacts in resected NSCLC.
               Research Paper: Autophagy and Cell Death
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IntroductIon
Lung cancer is the leading cause of cancer-related 
death worldwide [1]. Five-year survival remains poor, 
mainly due to late debut of symptoms and the presence 
of regional or distant metastases at diagnosis [2]. An 
increasing research effort has been invested in order to 
detect and validate novel biomarkers in non-small cell lung 
cancer (NSCLC). Although some of these markers have 
been adopted in current clinical practice, several potential 
biomarkers have not yet been adequately validated [3, 4]. 
Both tumor-preventing and tumor-promoting inflammation 
has been proved to play prognostic roles in several solid 
tumors [5-8]. Tumor-infiltrating cytotoxic T cells are of 
crucial importance in suppressing cancer development 
and controlling disease progression. Among the different 
cell subsets of tumor infiltrating lymphocytes (TILs), the 
most promising biomarker so far are CD8+ cytotoxic T 
lymphocytes, that are a pivotal component of the cell-
mediated antitumor immune responses [9]. In NSCLC, 
together with other malignancies, many studies have 
evaluated the clinical value of CD8+ cells alone or 
combined with other biomarkers, demonstrating a strong 
independent positive prognostic effect regardless of tissue 
compartments evaluated [10-16].
On the other hand, regulatory T cells (Tregs) are 
a subtype of CD4+T cells with immunosuppressive 
properties that express high levels of CD25 and low levels 
of CD127 on their cell surface [17, 18]. One of the most 
reliable phenotypic markers for Tregs is FOXP3, which 
is essential for their development and function and which 
has been broadly used for their detection [19]. Tregs are 
also characterized by the expression of other markers such 
as cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), 
lymphocyte activation gene 3 (LAG3) and glucocorticoid 
induced tumor necrosis factor receptor family related gene 
(GITR), or soluble immunosuppressive factors such as 
interleukin 10 (IL10) and transforming growth factor beta 
1 (TGBF1) [20]. The presence of FOXP3+ lymphocytes 
in cohorts of patients affected by different types of tumors, 
has been associated with a poor prognosis [21-25] or a 
better locoregional control and prognosis [26-29].
Altogether, the data obtained so far indicates that 
immune system-related biomarkers, and more specifically 
those involved in immunoregulation, may become useful 
in both development of the next generation biomarkers 
in NSCLC and as potential targets for novel therapies. 
Furthermore, it should be taken into consideration that the 
prognostic and predictive value of a given biomarker may 
be different or even opposite depending on which cellular 
compartment of the tumor it is expressed. Therefore, 
further studies using feasible and reliable techniques 
such as quantitative real-time PCR (RTqPCR), based on 
microdissected specimen, or immunohistochemistry (IHC) 
are essential to detect and validate new biomarkers. The 
aim of this study was to analyze the presence of immune 
markers at the mRNA and protein level in the tumor 
and tumor-near stroma compartment separately, and to 
investigate the relative proportion of conventional and 
regulatory T cells present in the tumor surrounding in 
order to understand their associations with the patients’ 




Detailed clinical and pathological information 
including age, gender, stage of disease and histology are 
summarized in Table 1. The median follow-up was 53.3 
[1-113] months. Of the 122 resected NSCLC patients 
included, 68 (55.7%) relapsed and 67 (54.9%) died during 
the follow-up period.
relative gene expression
All of the analyzed genes could be amplified 
using the selected primers/probes. We observed a strong 
overexpression, in both the tumor-near stroma and the 
tumor (measured as fold-change, X and range) of CD25 
(19.46X, [2.7-86.0], 11.59X, [0.3-54.2]), FOXP3 (4.96X, 
[0.2-67.4], 4.08X, [0.1-38.0]), CTLA4 (2.89X, [0.2-65.7], 
3.02X, [0.1-59.8]) and TGFB1 (3.24X, [0.6-16-6], 2.117X, 
[0.2-27.2]). In contrast, IL10 expression in the tumor 
compartment was downregulated (0.39X, [0.02-40.3]).
CD4+, CD8+, and FOXP3+ cell infiltration
In tonsil tissue samples, positive staining for CD4 
and CD8 was observed in the cytoplasm of lymphocytes, 
whereas FOXP3 staining was observed in the nucleus; the 
same pattern was seen in patient samples. There was no 
positive staining in the negative controls. Figure 1 shows 
a representative immunohistochemical staining of FOXP3, 
CD4 and CD8 in tumor and stroma compartments. CD4+ 
and CD8+ cells were detected in all assessable samples, 
although in 13 (15.5%) of the 84 samples CD4+ cells 
were only found in the tumor-near stromal compartment. 
FOXP3+ cells were detected in 80 (95.2%) of the 84 
assessable samples, although in 8 (10%) positive cells 
were only found in the tumor-near stromal compartment, 
and in one case (1.8%) positive cells were only found 
in the tumor compartment. For the three markers, there 
were significantly more positive T cells in the tumor-
near stroma than in the tumor compartment (pair-wise 
Wilcoxon test, p < 0.001). The number of positive cells 
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per HPF in the stromal compartment ranged from 1 to 
76 (median: 18.8) for CD4, from 3 to 73 (median: 29.8, 
mean: 29) for CD8 and from 0 to 45 (median: 11.6) for 
FOXP3. On the other hand, in the tumor compartment the 
number ranged from 0 to 21 (median: 1.8, mean: 3.5) for 
CD4, from 1 to 82 (median: 5.6) for CD8 and from 0 to 15 
(median: 1, mean: 1.6) for FOXP3. 
Patients’ tumors were classified as being weakly 
to strongly infiltrated by CD4+ and CD8+ immune 
cells in tumor and tumor-near stroma compartments 
according to the median calculated for each marker. For 
FOXP3 expression in the stromal compartment, 6% of 
the samples were negative, 55% expressed in less than 
10% of lymphocytes, 38% between 10% and 33%, and 
1.2% in more than 33%. For the tumor compartment, 14% 
were negative, 71% expressed in less than 10% positive 
lymphocytes, 13% in 10% and 33%, and 1.2% in more 
than 33%. 
correlation with clinicopathological variables
The expression, in both tumor and stromal 
compartments, of CD4 (p = 0.024 and p = 0.008, 
respectively), CD8 (p = 0.044 and p = 0.008, respectively), 
and LAG3 (p = 0.008, in both cases) were higher in 
adenocarcinoma (ADC) than in squamous cells carcinoma 
(SCC) patients. Moreover, higher IL10 expression was 
found in patients with stage I than stage II/IIIA disease 
(p = 0.027). As for the correlations with positive cell 
infiltration, we observed that higher levels (above the 
median) of CD4+ cells in the tumor stroma correlated 
with epidermal growth factor receptor (EGFR)-mutated 
patients (p = 0.047) and with ADC histology (p = 0.030). 
Furthermore, smaller tumors (less than 3.5 cm) were 
associated with a higher number of stromal CD8+ cells 
(p = 0.047). 
Prognostic value of gene expression markers and 
immune cell infiltration in tumor and tumor-near 
stroma
Survival analyses indicated that patients with high 
CD4 expression in the tumor compartment, dichotomized 
according to the median of its relative expression, had 
improved PFS (37.8 vs. 23 months, p = 0.042) and OS 
(81.2 vs. 42.9 months, p = 0.018). Similarly, high levels of 
CD8 expression in the tumor compartment were associated 
with improved PFS (81.2 vs. 19.4 months, p = 0.001) and 
OS (81.2 vs. 37.2 months, p < 0.001). The expression of 
CD8 in the stroma was also correlated with OS (74.3 vs. 
46.4 months, p = 0.032). With respect to FOXP3 high 
expression levels were correlated with longer PFS (35.3 
vs. 22.1 months, p = 0.020) and OS (NR vs. 37.2 months, 
p = 0.005).. Moreover, patients with high expression levels 
of LAG3 presented a better OS (69 vs. 36.2 months, p = 
0.023), and the same was observed for TGFB1 (74.3 vs. 
46.6 months, p = 0.032; Table 2). Kaplan-Meier plots for 
all these biomarkers are shown in supplementary Figure 1.
As for the immune cells markers detected by IHC, 
the presence of CD8+ cells in the tumor compartment, 
according to the median of positive cells infiltrating the 
tumor, was significantly associated with better PFS (56.8 
vs. 23 months, p = 0.026) and OS (73.9 vs. 40.4 months, 
p = 0.021; Figure 2A-2B), whereas patients with a higher 
percentage of FOXP3+ cells in the stromal compartment 
(more that 10% of positive lymphocytes) had shorter OS 
(37.2 vs. 68 months, p = 0.029; Figure 2C-2D; Table 2).
table 1: clinicopathological characteristics of the 
patients.
characteristics n %
Age at surgery 































Wild type 83 68
Mutated 14 11.5
NA 25 20.5
ADC, adenocarcinoma; SCC, squamous; NA; not 
analyzed; NS, non-specified; EGFR, epidermal growth 
factor receptor.
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Table 2:Univariate analysis of the gene expression and immune cells infiltration-related biomarkers.
os PFs
Variable Median survival (months) p-value
Median survival 
(months) p-value
Gene expression markers (N=122)
Tumoral CD4
High vs. low 81.2 vs. 42.9 0.018 37.8 vs. 23 0.042
Tumoral CD8
High vs. low 81.2 vs. 37.2 <0.001 81.2 vs. 19.4 0.001
Stromal CD8
High vs. low 74.3 vs. 46.4 0.032 29.1 vs. 25.6 0.237
Tumoral FOXP3
High vs. low NR vs. 37.2 0.005 35.3 vs. 22.1 0.020
Tumoral LAG3
High vs. low 69 vs. 36.2 0.023 30.1 vs. 22.1 0.107
Tumoral TGBF1
High vs. low 74.3 vs. 46.6 0.032 31.5 vs. 22.1 0.174
Ratio FOXP3stroma/ CD4tumor
High vs. low 46.6 vs. 81.2 0.012 19.4 vs. 37.8 0.013
Ratio FOXP3stroma/ CD8tumor
High vs. low 46.4 vs. 74.3 0.025 23 vs. 37.8 0.042
Immune cells markers (N=84)
Tumoral CD8+ cells
High vs .Low 73.9 vs. 40.4 0.021 56.8 vs. 23 0.026
Stromal FOXP3+ cells
High vs. Low 37.2 vs. 68 0.029 17.4 vs. 46.6 0.101
FOXP3+ stroma/ CD4+ tumor
High vs. Low 17.4 vs. 66.9 0.024 32.5 vs. 15.3 0.086
FOXP3+ stroma/ CD8+ tumor
High vs. Low 17.4 vs. 68.8 0.011 15.3 vs. 35.9 0.035
NR, not-reached; OS, overall survival; PFS, progression free survival. The p-value was calculated using the log-rank test.
table 3: results from the multivariate cox regression model for os and PFs.
os PFs
Variable Hr 95% cI p-value Hr 95% cI p-value
Gene expression markers (N=122)
Tumoral CD8 expression
High vs. low 0.169 0.064-0.447 <0.001 0.247 0.120- 0.507 <0.001
Immune cells markers (N=84)
Tumoral CD8+ cells
High vs. Low 0.386 0.175-0.850 0.018 0.305 0.137-0.680 0.004
Stromal FOXP3+ cells
High vs. Low 2.203 1.109-4.379 0.024 - - -
CI, confidence interval; HR, hazard ratio; OS, overall survival; PFS, progression free survival.
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Prognostic value of combined biomarkers
According to these results, and taking into account 
the biological interactions between the immune cells 
that express these markers, we decided to further study 
the prognostic value of the combination of conventional 
T cells (CD4 and CD8) and Tregs (FOXP3). First, we 
calculated new variables based on the ratio of these 
markers and used the median to dichotomized them as 
“low” or “high”. From the different combinations that 
were tested we observed that patients with a high FOXP3 
stroma/ CD4 tumor expression ratio have reduced PFS 
(19.4 vs. 37.8 months, p = 0.013) and OS (46.6 vs. 81.2 
months, p = 0.012; Figure 3A-3B; Table 2). As for the 
FOXP3 stroma/ CD8 tumor expression ratio, patients with 
high levels also presented worse PFS (23 vs. 37.8 months, 
p = 0.042) and OS (46.4 vs. 74.3 months, p = 0.025; Figure 
3C-3D; Table 2). 
To validate these results, available tissue samples 
from 84 of the122 patients were also assessed by IHC. 
Univariate survival analyses showed that patients with 
high FOXP3+ cells infiltration (more than 10% of positive 
lymphocytes) in the stroma and low CD4+ cells infiltration 
in the tumor (according to the median of positive cells 
infiltrating in the tumor) presented significantly worse OS 
(17.4 vs. 66.9 months, p = 0.024; Figure 4A-4B; Table 2). 
Moreover, patients with high infiltration of FOXP3+ cells 
in the stroma and low infiltration of CD8+ in the tumor 
also presented inferior PFS (15.3 vs. 35.9 months, p = 
0.035) and OS (17.4 vs. 68.8 months, p = 0.011; Figure 
4C-4D; Table 2).
Multivariate analysis
To determine whether any of the analyzed variables 
had independent prognostic impact, a multivariate 
analysis was performed, where significant biomarker and 
clinicopathological variables from the univariate analyses 
were entered in the analysis. Multivariate models for 
gene expression markers and for the immune cell markers 
assessed by IHC were carried out separately due to the 
different number of patients analyzed, and results are 
summarized in Table 3. As for the multivariate model 
including gene expression markers, PFS was adjusted 
for tumor size, which was significanty associated with 
PFS in the univariate analysis. The expression of CD8 in 
the tumor compartment was found to be an independent 
beneficial prognostic factor for both PFS (p < 0.001) and 
OS (p < 0.001).
A second multivariate model including immune cells 
Figure 1: representative immunohistochemical staining of FoXP3, cd4 and cd8 in tumor and stroma compartments. 
Original magnification X200. A. Low infiltration of FOXP3+ lymphocytes in tumor compartment, b. high infiltration of FOXP3+ lymphocytes 
in tumor compartment, c. low infiltration of FOXP3+ lymphocytes in stroma compartment, d. high infiltration of FOXP3+ lymphocytes 
in stroma compartment, e. low infiltration of CD4+ lymphocytes in tumor compartment, F. high infiltration of CD4+ lymphocytes in 
tumor compartment, G. low infiltration of CD4+ lymphocytes in stroma compartment and, H. high infiltration of CD4+ lymphocytes 
in stroma compartment, I. Low infiltration of CD8+ lymphocytes in tumor compartment, J. high infiltration of CD8+ lymphocytes in 
tumor compartment, K. low infiltration of CD8+ lymphocytes in stroma compartment, l. high infiltration of CD8+ lymphocytes in stroma 
compartment.
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markers determined by IHC was performed as well. In this 
model lymph node involvement and PS were included 
for both OS and PFS due to their significant correlation 
with survival observed in the univariate analysis. Here, 
results indicated that the presence of CD8+ cells in the 
tumor compartment and FOXP3+ cells in the stromal 
compartment, were independent prognostic biomarkers for 
OS (p = 0.018 and p = 0.024, respectively), and CD8+ cell 
infiltration in the tumor compartment was an independent 
prognostic factor also for PFS (p = 0.004).
dIscussIon
Over the past decade, the field of tumor immunology 
has been increasingly investigated. Today, it is generally 
accepted that the immune system plays a pivotal role in 
cancer, and provides prognostic and predictive markers. 
In our study, we have found that gene expression levels of 
CD8 in both tumor and tumor-near stroma compartments, 
and of CD4 only in the tumor compartment, were 
correlated with better outcomes. Furthermore, when the 
infiltration of cells positive for these markers was assessed 
Figure 2:  Kaplan-Meier plots for progression free survival and overall survival according to immune cells infiltration. 
A., b. Infiltration of CD8+ cells in tumor compartment and, c., d. infiltration of FOXP3+ cells in the stroma compartment. Densities were 
dichotomized as high and low infiltration according to the median of positive lymphocytes..
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by IHC, only the presence of CD8+ cells in the tumor 
compartment was correlated with survival. 
Although TILs have been widely assessed in the 
tumor microenvironment by IHC, little has been published 
regarding the expression of TIL-associated genes at the 
mRNA level. The latter approach is challenging because 
while it is highly feasible to distinguish between tumor 
versus stromal compartments by microscopy (IHC), 
this is more demanding when using RTqPCR, despite 
carefully performed tissue microdissections. On the 
other hand, the RTqPCR methods are more sensitive and 
objective, whereas IHC data are semiquantitative with the 
inconvenience that it may infer.
Among TILs, CD8+ cells form the effector arm 
of adaptive immunity with cytotoxic activity and are 
considered to have tumor preventive effects. We have 
observed that the presence of CD8+ cells in the tumor 
compartment, detected either by IHC or by RTqPCR, is 
highly associated with a beneficial prognosis. Accordingly, 
Ruffini et al. observed that CD8+ cells were associated 
with prolonged survival in 1290 stage I-IIIA NSCLC 
patients, but that an independent prognostic impact was 
Figure 3: Kaplan-Meier plots for progression free survival and overall survival according to the ratios for conventional 
and regulatory gene expression markers. A., b. FOXP3 stroma/ CD4 tumor expression ratio and, c., d. FOXP3 stroma/ CD8 tumor 
expression ratio. Gene expression levels were dichotomized according to the median.
Oncotarget52856www.impactjournals.com/oncotarget
associated with squamous cell carcinomas only [30]. At 
about the same time Al-Shibli et al. observed that high 
CD8+ lymphocyte infiltration, in both tumor and stromal 
areas, was associated with better survival in 335 resected 
stage I-IIIA NSCLC patients [10]. Recently, it has been 
demonstrated that the density of stromal CD8+ cells, due 
to its significant independent prognostic impact, might 
be a good candidate marker for establishing a TNM-
Immunoscore in resected NSCLC [11]. 
In contrast, the presence of CD4+ cells in different 
types of cancer [31-33] has yielded contradictory results 
regarding prognosis. In lung tumors, the presence 
of stromal CD4+ lymphocytes has, in general, been 
correlated with improved survival [10, 34, 35]. Our results 
obtained by IHC are consistent with previous NSCLC 
studies. In a 50-gene signature study of stage I/II NSCLC 
tumors the presence of CD4+ cells did not correlate with 
survival [36]. This discrepancy can be explained by the 
fact that CD4+ TILs form a heterogeneous population of 
cells with different phenotypes and even with opposing 
actions in the tumor microenvironment [9].
In our study, FOXP3+ provided opposite results 
Figure 4: Kaplan-Meier plots for progression free survival and overall survival according to the FOXP3+ cells 
proportion to conventional t cells markers. A., b. Combination of FOXP3+ cells in the stroma/CD4+ cells in the tumor, and c., d. 
combination of FOXP3+ cells in the stroma/CD8+ cells in the tumor.
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according to compartment analyzed and methodology. 
While FOXP3 gene expression levels in the tumor were 
significantly associated with better outcomes, the presence 
of FOXP3+ cells in the stroma had the opposite effect. 
In previous studies with different types of cancer, the 
presence of FOXP3+ cells has been associated with both 
poor [37, 38] and improved OS [39-41], although mRNA 
expression levels were not assessed in any of these studies. 
A possible explanation for this observation is the extreme 
heterogeneity of resected carcinomas, the mixed patterns 
of adenocarcinomas [42], and the fact that we could not 
select areas representative of all the major tissue patterns 
present. Additionally, cancer cells positive for FOXP3 
have been detected in several distinct types of cancer 
[37,43] that could attenuate the unfavorable prognostic 
influence of the tumor-infiltrating Tregs detected by 
IHC. In contrast, the presence of FOXP3+ cells or 
Tregs in the stroma was correlated with worse survival. 
Shimizu et al. demonstrated that patients with NSCLC 
(stages I-IIIB) containing three or more infiltrating Treg 
cells/10 HPFs in the tumor tissue had significantly worse 
recurrence-free survival (RFS), and among patients with 
node-negative NSCLC, Tregs were an independent poor 
prognostic factor [38]. An increased Treg count was 
also found to be associated with worse OS and RFS in 
another study with I-IIIA stage NSCLC [37]. Furthermore, 
a high density of stromal FOXP3+ cells was associated 
with a shorter recurrence-free probability [44]. Another 
possible explanation for this results may come from 
the heterogeneous phenotypes described for FOXP3+ 
regulatory T lymphocytes [45], their epigenetic regulation 
[46] or the presence of exhausted phenotypes [47]. Our 
results indicate that there is a great variability of each 
particular subpopulation between patients and this aspect 
could affect to the designation of a potential biomarker. 
This variability can be explained because immune cells 
are more prone to be located in the stroma than within 
the tumor compartment. As for the difference between 
the particular subpopulations, it was expected to obtained 
similar data for CD4 and CD8 positive cells, but not in 
the FOXP3 positive cells case. This is due to the fact that 
FOXP3 cells or regulatory T cells are less common than 
conventional T cell. All these observations emphasize the 
importance of assessing the location and type of immune 
cells within the tumor microenvironment.
Our data shows that patients with high expression 
levels of LAG3 in the tumor compartment presented a 
better outcome. LAG3 functions as an immune checkpoint 
and has a role in enhancing the function of Treg cells 
[48]. To the best of our knowledge, the prognostic value 
of LAG3 has not previously been assessed in NSCLC 
or any other tumor type. Another marker that presented 
a significant association with OS when expressed in the 
tumor compartment was TGFB1. This marker plays a 
critical and dual role in the progression of human cancer 
[49-52] and in NSCLC a recently published work reported 
that TGFB1 positive patients showed remarkably longer 
survival than the others [53]. 
We also studied the prognostic value of conventional 
TILs such as CD4+ and CD8+ cells in combination with 
FOXP3+ cells. In addition to type, density, and location, 
we have also demonstrated that the relative proportion 
of pro- and antitumor immune cells should be studied 
when analyzing TILs. According to our data, the ratio 
of FOXP3+ vs CD4+ or CD8+ cells in both the tumor 
and stromal compartment had a prognostic value. In this 
regard, it was observed that patients with stage I NSCLC 
with a higher proportion of tumor Tregs relative to CD3+ 
TILs, a pan-T cell marker that does not differentiate among 
helper and cytotoxic T cells, had a significantly higher 
risk of recurrence [54]. In a previous study including 
stage I adenocarcinomas, tumors containing high stromal 
FOXP3+ and low stromal CD3+ were considered to be 
more progressive, and FOXP3+ high versus stromal CD3+ 
low was found to be a strong predictor of recurrence 
[44]. To the best of our knowledge, our study is the first 
reporting the prognostic value of Tregs versus cytotoxic 
or helper TILs in the tumor or tumor-near stromal 
compartment.
In the multivariate analysis, CD8 gene expression 
by means of RTqPCR and infiltrating CD8+ cells 
evaluated by IHC in the tumor compartment were found 
to be independent prognostic factors for OS and PFS, 
probably indicating an ongoing immune response against 
the tumor [55]. Furthermore, FOXP3+ cells in the tumor-
near stroma compartment was an independent negative 
prognostic factor for OS, emphasizing the importance of 
assessing the location of immune cells within the tumor 
microenvironment.
In conclusion, although some papers address 
the role in CD8 and Foxp3 in lung cancer, the original 
aspects of this study lies in the fact that the tumor and 
stroma compartment of the tumor tissue have been 
investigated separately with a double approach using IHC 
and RTqPCR. Thus, the presence of CD8+ TILs in the 
tumor compartment, both at mRNA level and detected by 
IHC, identified a group of patients with longer survival, 
suggesting that an activated immune response might have 
an important role in patient outcome. In contrast, the 
presence of FOXP3+ cells in the stromal compartment 
identified a subset of patients with worse survival. This 
association was also specifically observed when the 
density of CD8+ and CD4+ in the tumor was low, but not 
in other cases, suggesting the importance of assessing the 
relative proportion of conventional and regulatory T cells 
present in the tumor surroundings. Further investigations 
and prospective clinical studies will be required to validate 
these results and their possible therapeutic implications.
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MAterIAls And MetHods
Patients and tissue samples
In this retrospective study, 122 patients from 
Consorcio Hospital General Universitario de Valencia 
with a clinical and histological diagnosis of stage I to IIIA 
(according to the American Joint Committee on Cancer 
staging manual) NSCLC and diagnosed between 2004 and 
2013, were included. None of the patients received chemo- 
or radiotherapy prior to surgery. The study was conducted 
in accordance with the Declaration of Helsinki, and the 
institutional ethical review board approved the protocol. 
Reported recommendations for tumor marker prognostic 
studies (REMARK) criteria were followed throughout the 
study [56]. Progression-free survival (PFS) was estimated 
as the time from surgery to recurrence or death from the 
disease, whereas overall survival (OS) was defined as the 
time from diagnosis to the date of death or last follow 
up. Formalin-fixed, paraffin-embedded (FFPE) samples 
obtained from tumor resections in these patients were used 
in this study. 
Gene expression analysis
Laser capture microdissection was performed in 
order to separately collect tumor and tumor-near stroma 
tissue areas from 122 FFPE tumor specimens. For this 
purpose, a LMD6500 Leica laser microdissection system 
(Leica, Wetzlar, Germany) was used with the support 
of a Hitachi HV-D20 camera (Hitachi Kokusai Electric, 
Tokyo, Japan). RNA was isolated using a RecoverAllTM 
Total Nucleic Acid Isolation Kit (Ambion, Austin, TX, 
USA) following the manufacturer’s recommendations. 
Reverse transcription (RT) reactions were performed 
from 100 ng of total RNA using random hexanucleotides 
and a High-Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems, Foster City, CA, USA) following 
the manufacturer’s instructions. The thermal cycling 
conditions were as follows: 10 min at 25˚ C, 120 min at 
37˚ C, and 5 s at 85˚ C. A TaqMan® PreAmp Master Mix 
Kit (Applied Biosystems) was used for preamplification 
to increase the quantity of specific cDNA target. The 
preamplification conditions were as follows: 10 min at 95˚ 
C for enzyme activation, followed by 10 cycles of 15 s at 
95˚ C and, finally, 4 min at 60˚ C.
RTqPCR was performed to analyze the relative 
expression of CD4, CD8, FOXP3, CD25, CD127, CTLA4, 
LAG3, GITR, TGFB1 and IL10 genes with assays based on 
hydrolysis probes using 1 µl of cDNA, a Universal Master 
Mix, and a TaqMan Gene Expression Assay (Applied 
Biosystems), in a 5 µl final reaction volume. GAPDH and 
CDKN1B were selected as endogenous controls by using 
the GeNorm algorithm. The thermal cycling parameters 
were as follows: 2 min at 50˚C and 10 min at 95˚C 
followed by 40 cycles of 15 s at 95˚C and 1 min at 60˚C. 
For efficiency calculations, we used random-primed qPCR 
Human Reference cDNA (Clontech, USA). Relative gene 
expression levels were expressed as the ratio of target gene 
expression to the geometric mean of the endogenous gene 
expression by using the Pfaffl formula [57]. We considered 
a gene to be overexpressed in the tumor or tumor-near 
stroma compartment when the median of the relative gene 
expression referred to the human cDNA was higher than 
2 and underexpressed when it was less than 0.5. Gene 
expression levels were dichotomized as “high” and “low” 
according to the median of each case.
Immunohistochemistry
In this study, the expression of FOXP3, CD4, 
and CD8 was evaluated in 84 of the FFPE samples 
included using a Dako Autostainer Link 48 and the Dako 
EnVision™ FLEX detection system (Dako, Burlington, 
Canada). Briefly, sections were dried and loaded into the 
PT Link instrument where the antigen retrieval/dewaxing 
process took place. The sections were transferred to the 
Autostainer Link 48 instrument where the endogenous 
peroxidase activity was quenched with peroxidase 
blocking reagent for 10 minutes. Immunostaining was 
carried out with Dako FLEX Ready to-Use format for 
CD4 (Clone 4B12, Dako) and CD8 (Clone C8/144B, 
Dako), and with a primary antibody diluted at 1:300 with 
Dako Antibody Diluent (Dako) for FOXP3 (Clone 236A/
E7, Abcam, Cambridge, MA, USA). After incubation 
with the primary antibody a detection system chromogen 
(3,3’-diaminobenzidine, DAB) was used. Finally, the 
sections were washed, lightly counterstained with 
hematoxilin, dehydrated, and mounted. Normal human 
tonsil tissue was used as a positive control for the three 
antibodies, and negative controls were included by 
omitting the primary antibody.
Quantification of immunohistochemical staining
The slides were independently examined by two 
researchers (SC, JF or MM), all were blinded to cases 
and data. Before initiating the scoring, controls were 
reviewed for quality assurance, compartments for scoring 
were agreed upon and the semiquantitative scale to be 
used was defined. To evaluate FOXP3 immunostaining, 
the percentage of nuclear-stained lymphocytes present in 
the tumor and tumor-near stroma was defined and graded 
on a scale of 0-3 according to the percentage of positive 
lymphocyte cells: 0 = no staining, 1 = less than 10% 
positive, 2 = 10-32% positive, 3 = 33% or more positive. 
Furthermore, high power fields (HPFs; magnification 
X400) were analyzed in 10 tumor or stromal areas per 
sample and the absolute number of FOXP3+ lymphocytes 
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was determined and then averaged. CD4+ and CD8+ 
lymphocytes were also counted in 10 HPFs for both tumor 
and tumor-near stroma areas, and were then averaged. 
We used 10% positive lymphocytes as a low-high cutoff 
value for FOXP3+ cell dichotomization. High power fields 
(HPFs; magnification X400) were analyzed in 10 tumor 
or stromal areas per sample and the absolute number of 
CD4+ and CD8+ cells was determined, and the median 
was obtained in each case. The median of positive cells 
was used as a cutoff in both cases. Examples of IHC 
images representing different infiltration scores in tumor 
and tumor-near stroma locations are shown in Figure 1. 
statistical analysis
Continuous variables were compared by non-
parametric Mann-Whitney U and Kruskall-Wallis tests. 
A Spearman rank test was used to test for correlations 
between continuous variables. Correlated variables were 
not included in the same multivariate model and the 
association between dichotomized variables was evaluated 
by the Chi-square test. Survival analysis was performed 
using a univariate Kaplan-Meier (log-rank) test method 
with clinicopathological variables, dichotomized gene 
expression marker levels, and density of immune cell 
infiltration levels. Finally, to assess the independent 
value of the tested biomarkers, a Cox proportional hazard 
model for multivariate analyses was used. All significant 
variables from the univariate analyses were entered into 
the multivariate analyses in a forward stepwise Cox 
regression analysis. A probability of 95% (P < 0.05) was 
considered statistically significant for all analyses. The 
statistical analyses were done using the Statistical Package 
for the Social Sciences (SPSS, Chicago, IL, USA) version 
15.0.
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